Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$211.17 USD

211.17
2,255,897

-16.27 (-7.15%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $210.00 -1.17 (-0.55%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bio-Rad (BIO) Beats Q1 Earnings Estimates, Withdraws View

by Zacks Equity Research

Bio-Rad's (BIO) first-quarter 2020 results reflect strong segmental performance boosted by coronavirus-led increased testing demand.

Exact Sciences' (EXAS) Q1 Earnings Fall Y/Y, Margin Expands

by Zacks Equity Research

Exact Sciences' (EXAS) first-quarter 2020 results reflect strong performance by Screening segment amid the coronavirus-led economic crisis.

Nevro (NVRO) Earnings and Revenues Beat Estimates in Q1

by Zacks Equity Research

Nevro's (NVRO) domestic revenues improved on a year-over-year basis in Q1.

Becton Dickinson (BDX) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Becton Dickinson's (BDX) second-quarter results reflect solid performance by the core Life Sciences and Interventional segments.

Myriad Genetics (MYGN) Lags Q3 Earnings Estimates, Cancels View

by Zacks Equity Research

Myriad Genetics (MYGN) reports revenue declines in both reporting segments in Q3 resulting from coronavirus-led business disruptions.

CVS Health (CVS) Q1 Earnings Top Estimates, Costs Escalate

by Zacks Equity Research

Within CVS Health's (CVS) Retail/LTC, the coronavirus pandemic results in greater use of 90-day prescriptions and early refills of maintenance medications in the quarter.

Haemonetics (HAE) Q4 Earnings Lag Estimates, Margins Expand

by Zacks Equity Research

Haemonetics' (HAE) fourth-quarter fiscal 2020 results reflect strong performance by Plasma segment despite dismal overall performance during the coronavirus-led crisis.

Inogen's (INGN) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Inogen (INGN) reported growth in business-to-business international and domestic revenues in Q1.

DaVita (DVA) Earnings and Revenues Beat Estimates in Q1

by Zacks Equity Research

DaVita's (DVA) dialysis services in the United States showcased solid results in Q1.

Cardiovascular Systems (CSII) Reports Q3 Loss, Lower Margin

by Zacks Equity Research

Cardiovascular Systems (CSII) witnesses a significant decline in procedure volumes in Q3 for patients treated with orbital atherectomy devices.

PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

PerkinElmer's (PKI) first-quarter results benefit from growth in Discover & Analytics Solutions segment. However, forex remains a woe.

Henry Schein (HSIC) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Henry Schein (HSIC) sees dismal performance by Dental arm in Q1 due to disruptions resulting from the coronavirus pandemic.

Tandem Diabetes (TNDM) Q1 Loss Widens, Revenues Top Estimates

by Zacks Equity Research

Tandem Diabetes' (TNDM) strong domestic pump sales and the company's expansion in international markets boost the top line.

Teleflex (TFX) Earnings and Revenues Beat Estimates in Q1

by Zacks Equity Research

Teleflex's (TFX) first-quarter 2020 results reflect sales growth across few major segments despite the coronavirus pandemic.

Hill-Rom's (HRC) Q2 Earnings Top Estimates, Margins Expand

by Zacks Equity Research

Hill-Rom (HRC) benefits from increased product demand due to the coronavirus outbreak.

Syneos Health (SYNH) Tops Q1 Earnings Estimates, Margins Down

by Zacks Equity Research

The coronavirus impact results in inaccessibility of several of Syneos Health's (SYNH) clinical trial sites.

Illumina (ILMN) Beats Q1 Earnings Estimates, Withdraws View

by Zacks Equity Research

Illumina (ILMN) exhibits robust growth in the first quarter of 2020 fueled by strong performance of the sequencing consumable subsegment despite the coronavirus pandemic.

Hologic (HOLX) Beats Q2 Earnings Estimates, Withdraws View

by Zacks Equity Research

Hologic (HOLX) exhibits robust segmental growth in second-quarter fiscal 2020, fueled by strong performance by the Diagnostics segment amid the coronavirus pandemic.

Biotech Stocks Earnings Roster for Apr 30: AMGN, GILD & More

by Zacks Equity Research

Let us take a look at what is in store for some of the biotech stocks, which are scheduled to report on Apr 30.

Will Strong HIV Sales Drive Gilead's (GILD) Q1 Earnings?

by Zacks Equity Research

Investors will focus on the HIV franchise's performance and the uptake of Yescarta along with updates on the experimental coronavirus treatment when Gilead (GILD) reports first-quarter 2020 results.

The Zacks Analyst Blog Highlights: Intel, Novartis, Toyota Motor, Union Pacific and Biogen

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Intel, Novartis, Toyota Motor, Union Pacific and Biogen

Focus on Coronavirus Treatments to Boost Biotech Stocks

by Zacks Equity Research

With the coronavirus pandemic raging on, biotech companies are in focus as they are racing against time to evaluate every possible therapy to combat the spread.

Sheraz Mian headshot

Top Research Reports for Intel, Novartis & Toyota

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Intel (INTC), Novartis (NVS) and Toyota Motor (TM).

Vertex (VRTX) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Biogen (BIIB) Stock Down Despite Q1 Earnings & Sales Beat

by Zacks Equity Research

Biogen (BIIB) beats estimates for both earnings and sales in the first quarter. Stock declines.